Search hospitals > Ohio > Columbus
Ohio State University Comprehensive Cancer Center
Claim this profileColumbus, Ohio 43210
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Relapse
Conducts research for Cancer
Conducts research for Cystic Tumor
806 reported clinical trials
145 medical researchers
Summary
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Relapse, Cancer, Cystic Tumor and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 829 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Alice Mims, Uma Borate, MD, and Michael V Knopp, MD, PhD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Floor Backes, MDOhio State University Comprehensive Cancer Center2 years of reported clinical research
Expert in Parotid Gland Cancer
Expert in Ovarian Cancer
22 reported clinical trials
60 drugs studied
Alice MimsOhio State University Comprehensive Cancer Center6 years of reported clinical research
Expert in Acute Myeloid Leukemia
Expert in Adult T-Cell Leukemia/Lymphoma
19 reported clinical trials
42 drugs studied
Uma Borate, MDOhio State University Comprehensive Cancer Center3 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
17 reported clinical trials
31 drugs studied
Michael V Knopp, MD, PhDThe Ohio State University Wexner Medical Center2 years of reported clinical research
Studies Anterior Cruciate Ligament Injury
Studies Digital PET/CT Imaging
15 reported clinical trials
35 drugs studied
Clinical Trials running at Ohio State University Comprehensive Cancer Center
Breast Cancer
Lung Cancer
Breast cancer
Ovarian Cancer
Prostate Cancer
Parotid Gland Cancer
Adult T-Cell Leukemia/Lymphoma
Fallopian Tube Cancer
Chronic Lymphocytic Leukemia
Kidney Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Ohio State University Comprehensive Cancer Center?
Ohio State University Comprehensive Cancer Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Relapse, Cancer, Cystic Tumor and other specialties. Ohio State University Comprehensive Cancer Center is involved with conducting 806 clinical trials across 829 conditions. There are 145 research doctors associated with this hospital, such as Floor Backes, MD, Alice Mims, Uma Borate, MD, and Michael V Knopp, MD, PhD.
Where is Ohio State University Comprehensive Cancer Center located?
The Ohio State University Comprehensive Cancer Center is located at 300 West 10th Avenue, Columbus, OH 43210. For access, take Medical Center Drive to Dodd Drive, turn left, and follow signs to the Wexner Medical Center Garage. Alternatively, use Kinnear Road to King Avenue, turn left onto King, and then left onto Cannon Drive to reach the hospital.
Who should I call to ask about financial aid or insurance network?
**Ohio State University Comprehensive Cancer Center - Contact Information**
- **Financial Counseling Department:** 614-293-0860
- **Financial Assistance:** 614-293-0860
- **Medication Assistance Program:** 614-293-3868
- **Patient Billing Customer Service:** 614-293-2100
- **Medicaid Assistance:** 614-293-0860, option 2
For more details or to apply for financial assistance, please visit the Financial Assistance page on our website.
What insurance does Ohio State University Comprehensive Cancer Center accept?
The Ohio State University Comprehensive Cancer Center (OSUCCC) accepts a wide range of insurance plans, including Medicaid, Medicare, and various exchange health plans. For Medicaid, accepted plans include AmeriHealth Caritas, Buckeye Community Health Plan, CareSource, Humana Healthy Horizons, and Medicaid Ohio Traditional. Medicare recipients are covered under all traditional plans and Medigap coverage, while exchange health plans accepted include CareSource Marketplace, Molina Healthcare of Ohio, and Buckeye AmBetter.
What awards or recognition has Ohio State University Comprehensive Cancer Center received?
The Ohio State University Comprehensive Cancer Center (OSUCCC) in Columbus, Ohio, has been a National Cancer Institute (NCI)-designated comprehensive cancer center since 1976, showcasing its commitment to excellence in research, patient care, education, and community outreach. It has garnered significant funding for research and care, including NCI grants for phase 1, 2, and 3 clinical trials of novel cancer drugs. Additionally, the OSUCCC supports initiatives such as the Pelotonia Institute for Immuno-Oncology and the Center for Cancer Engineering.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.